NCT00230620 Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
| NCT ID | NCT00230620 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Telangiectasia, Hereditary Hemorrhagic |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 1998-12 |
| Primary Completion | 2030-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 1998-12 with a primary completion date of 2030-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will examine genes involved in the vascular dysplasia Hereditary haemorrhagic telangiectasia i(HHT)
Eligibility Criteria
Inclusion Criteria: * Member of family affected by HHT Exclusion Criteria: * Unable or unwilling to provide informed consent for DNA sample
Contact & Investigator
Claire L Shovlin
PRINCIPAL INVESTIGATOR
Imperial College London
Frequently Asked Questions
Who can join the NCT00230620 clinical trial?
This trial is open to participants of all sexes, studying Telangiectasia, Hereditary Hemorrhagic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00230620 currently recruiting?
Yes, NCT00230620 is actively recruiting participants. Contact the research team at c.shovlin@imperial.ac.uk for enrollment information.
Where is the NCT00230620 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT00230620 clinical trial?
NCT00230620 is sponsored by Imperial College London. The principal investigator is Claire L Shovlin at Imperial College London. The trial plans to enroll 1,000 participants.